Posted by Michael Wonder on 22 Apr 2021
NICE recommends new treatment for rare blood disorder
22 April 2021 - Hundreds of people with a rare blood disorder have access to a new treatment regimen following draft guidance from NICE.
In draft guidance published 15 April 2021, NICE has recommended ravulizumab (Ultomiris, Alexion Pharmaceuticals) as a treatment for paroxysmal nocturnal haemoglobinuria.
